Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Opioid Use Often Persists in Workers’ Compensation Claimants
WEDNESDAY, Oct. 31, 2018 (HealthDay News) — Many patients in a workers’ compensation cohort have persistent opioid use, according to a study published online Oct. 26 in JAMA Network Open.
Antibiotics, Acid Suppressants in Infancy May Up Obesity Risk
WEDNESDAY, Oct. 31, 2018 (HealthDay News) — Prescription of antibiotics and acid-suppressing medications in early childhood is associated with an increased risk for obesity, according to a study published online Oct. 30 in Gut.
Link Between Statins, Non-CVD Outcomes Lacks Evidence
WEDNESDAY, Oct. 31, 2018 (HealthDay News) — There is a lack of convincing evidence for an association between statin use and non-cardiovascular disease (CVD) outcomes, according to a review published in the Oct. 16 issue of the Annals of Internal Medicine.
Abstract/Full Text (subscription or payment may be required)
Angiotensin-Converting Enzyme Inhibitors May Up Lung CA Risk
TUESDAY, Oct. 30, 2018 (HealthDay News) — The use of angiotensin-converting enzyme inhibitors (ACEIs) is associated with an increased risk for lung cancer compared with angiotensin receptor blockers, according to a study published online Oct. 24 in the BMJ.
Pilot Studies May Shed Light on How to Treat Lymphedema
TUESDAY, Oct. 30, 2018 (HealthDay News) — Treatment with ketoprofen may improve the skin biology in lymphedema, with improvements noted in histopathology and skin thickness, according to a study published online Oct. 18 in JCI Insight.
Health Officers Express Concerns About Vaccine Exemptions
MONDAY, Oct. 29, 2018 (HealthDay News) — After the passage of Senate Bill 277 (SB277) in California, which eliminated nonmedical vaccine exemptions for school entry, health officers and immunization staff reported concerns including an increase in medical exemptions, according to a study published online Oct. 29 in Pediatrics.
In Complicated UTI, Cefiderocol Noninferior to Imipenem-Cilastin
MONDAY, Oct. 29, 2018 (HealthDay News) — For complicated urinary tract infections caused by multidrug-resistant Gram-negative uropathogens, the siderophore cephalosporin cefiderocol is non-inferior to imipenem-cilastatin, according to a study published online Oct. 25 in The Lancet Infectious Diseases.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA
Homicide, Suicide, and Overdose Leading Causes of Maternal Death 
Model Predicts Poor Outcomes Within 30 Days of a Before Medically Advised Discharge 
Fewer Than Half of Drug Overdose Survivors Go to the Hospital 
2000 to 2023 Saw Rise in Pediatric Exposure to Medications, Supplements 
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus 
Therapies Compared for Newly Diagnosed Multiple Sclerosis 
Initial Rx Length Tied to Long-Term Use of Z-Drugs 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
.jpg)